Publicaciones en colaboración con investigadores/as de Instituto de Biología Molecular y Celular del Cáncer de Salamanca / Centro de Investigación del Cáncer (19)

2023

  1. An amino acid transporter subunit as an antibody-drug conjugate target in colorectal cancer

    Journal of experimental & clinical cancer research : CR, Vol. 42, Núm. 1, pp. 200

  2. Chemical-proteomics Identify Peroxiredoxin-1 as an Actionable Target in Triple-negative Breast Cancer

    International Journal of Biological Sciences, Vol. 19, Núm. 6, pp. 1731-1747

2022

  1. Surfaceome analyses uncover CD98hc as an antibody drug-conjugate target in triple negative breast cancer

    Journal of Experimental and Clinical Cancer Research, Vol. 41, Núm. 1

2021

  1. MZ1 co-operates with trastuzumab in HER2 positive breast cancer

    Journal of Experimental and Clinical Cancer Research, Vol. 40, Núm. 1

  2. Preclinical and clinical characterization of fibroblast-derived neuregulin-1 on trastuzumab and pertuzumab activity in HER2-positive breast cancer

    Clinical Cancer Research, Vol. 27, Núm. 18, pp. 5096-5108

2020

  1. Pharmacological screening and transcriptomic functional analyses identify a synergistic interaction between dasatinib and olaparib in triple-negative breast cancer

    Journal of Cellular and Molecular Medicine, Vol. 24, Núm. 5, pp. 3117-3127

2019

  1. Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer

    Journal of Experimental and Clinical Cancer Research, Vol. 38, Núm. 1

  2. Screening and preliminary biochemical and biological studies of [RuCl(p-cymene)(N, N-bis(diphenylphosphino)-isopropylamine)][BF4] in Breast Cancer Models

    ACS Omega, Vol. 4, Núm. 8, pp. 13005-13014

2017

  1. Regulation of the prometastatic neuregulin–MMP13 axis by SRC family kinases: therapeutic implications

    Molecular Oncology, Vol. 11, Núm. 12, pp. 1788-1805

2014

  1. Achilles' heel of triple negative cancer

    Oncoscience

  2. Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer

    Oncogene, Vol. 33, Núm. 2, pp. 148-156

2009

  1. DNA DSBs Induction by Zalypsis, a Novel Marine Compound, Results in Potent Antimyeloma Activity

    CLINICAL LYMPHOMA & MYELOMA

2008

  1. Expression of c-Kit isoforms in multiple myeloma: Differences in signaling and drug sensitivity

    Haematologica, Vol. 93, Núm. 6, pp. 851-859

  2. Neuregulins and cancer

    Clinical Cancer Research, Vol. 14, Núm. 11, pp. 3237-3241

2007

  1. Erk5 is activated and acts as a survival factor in mitosis

    Cellular Signalling, Vol. 19, Núm. 9, pp. 1964-1972

  2. Neuregulin expression modulates clinical response to trastuzumab in patients with metastatic breast cancer

    Journal of Clinical Oncology, Vol. 25, Núm. 19, pp. 2656-2663

  3. The extracellular linker of pro-neuregulin-α2c is required for efficient sorting and juxtacrine function

    Molecular Biology of the Cell, Vol. 18, Núm. 2, pp. 380-393

2005

  1. Activation of ErbB2 by overexpression or by transmembrane neuregulin results in differential signaling and sensitivity to herceptin

    Cancer Research, Vol. 65, Núm. 15, pp. 6801-6810

  2. Multifunctional role of Erk5 in multiple myeloma

    Blood, Vol. 105, Núm. 11, pp. 4492-4499